Evidence map›Paper›PMID 32584956›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Incidence, Etiology, and Severity of Acute Gastroenteritis Among Prospectively Enrolled Patients in 4 Veterans Affairs Hospitals and Outpatient Centers, 2016-2018.

Cristina V Cardemil, Neha Balachandran, Anita Kambhampati, Scott Grytdal, Rebecca M Dahl, Maria C Rodriguez-Barradas, Blanca Vargas, David O Beenhouwer, Karen V Evangelista, Vincent C Marconi and 11 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05876585 (A Randomized, Double-Blinded, Placebo-Controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Ondansetron), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.4field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05876585 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

A Randomized, Double-Blinded, Placebo-Controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis

TypeinterventionalSponsorGenuine Research Center, EgyptRan2025 to 2025Enrolled126ConditionsGastroenteritisArmsOndansetron 8 mg ampoule, Metoclopramide 10 mg ampoule
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Evaluating outpatient diagnostic stewardship of comprehensive polymerase chain reactionAntimicrobial stewardship & healthcare epidemiology : ASHE · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 1 country.

Cristina V CardemilDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Neha BalachandranCherokee Nation Assurance, Arlington, Virginia, contracting agency to the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA.
Anita KambhampatiCherokee Nation Assurance, Arlington, Virginia, contracting agency to the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA.
Scott GrytdalDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Rebecca M DahlMaximus Federal, contracting agency to the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA.
Maria C Rodriguez-BarradasInfectious Diseases Section, Michael E. DeBakey VA Medical Center and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Blanca VargasInfectious Diseases Section, Michael E. DeBakey VA Medical Center and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
David O BeenhouwerVA Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Karen V EvangelistaVA Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Vincent C MarconiAtlanta VA Medical Center, Atlanta, Georgia, USA.
Kathryn L MeagleyAtlanta VA Medical Center, Atlanta, Georgia, USA.
Sheldon T BrownJames J. Peters VA Medical Center, Bronx, New York, USA.
Adrienne PereaJames J. Peters VA Medical Center, Bronx, New York, USA.
Cynthia Lucero-ObusanPublic Health Surveillance and Research, Department of Veterans Affairs, Washington, DC, USA.
Mark HolodniyPublic Health Surveillance and Research, Department of Veterans Affairs, Washington, DC, USA.
Hannah BrowneCherokee Nation Assurance, Arlington, Virginia, contracting agency to the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA.
Rashi GautamDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Michael D BowenDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jan VinjéDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Umesh D ParasharDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Aron J HallDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
National Center for Immunization and Respiratory Diseases · USCenters for Disease Control and Prevention · USCherokee Nation · USUniversity of California, Los Angeles · USAtlanta Medical Center · USAtlanta VA Medical Center · USBaylor College of Medicine · USIcahn School of Medicine at Mount Sinai · USJames J. Peters VA Medical Center · USMichael E. DeBakey VA Medical Center · USStanford University · USVA Palo Alto Health Care System · US

Funding

Atlanta VAMCCDC HHSIntramural CDC HHS CC999999the Emory Center for AIDS Research
6 · The paper itself

Abstract

backgroundAcute gastroenteritis (AGE) burden, etiology, and severity in adults is not well characterized. We implemented a multisite AGE surveillance platform in 4 Veterans Affairs Medical Centers (Atlanta, Georgia; Bronx, New York; Houston, Texas; and Los Angeles, California), collectively serving >320 000 patients annually.

methodsFrom 1 July 2016 to 30 June 2018, we actively identified inpatient AGE case patients and non-AGE inpatient controls through prospective screening of admitted patients and passively identified outpatients with AGE through stool samples submitted for clinical diagnostics. We abstracted medical charts and tested stool samples for 22 pathogens by means of multiplex gastrointestinal polymerase chain reaction panel followed by genotyping of norovirus- and rotavirus-positive samples. We determined pathogen-specific prevalence, incidence, and modified Vesikari severity scores.

resultsWe enrolled 724 inpatients with AGE, 394 non-AGE inpatient controls, and 506 outpatients with AGE. Clostridioides difficile and norovirus were most frequently detected among inpatients (for AGE case patients vs controls: C. difficile, 18.8% vs 8.4%; norovirus, 5.1% vs 1.5%; P < .01 for both) and outpatients (norovirus, 10.7%; C. difficile, 10.5%). The incidence per 100 000 population was highest among outpatients (AGE, 2715; C. difficile, 285; norovirus, 291) and inpatients ≥65 years old (AGE, 459; C. difficile, 91; norovirus, 26). Clinical severity scores were highest for inpatient norovirus, rotavirus, and Shigella/enteroinvasive Escherichia coli cases. Overall, 12% of inpatients with AGE had intensive care unit stays, and 2% died; 3 deaths were associated with C. difficile and 1 with norovirus. C. difficile and norovirus were detected year-round with a fall/winter predominance.

conclusionsC. difficile and norovirus were leading AGE pathogens in outpatient and hospitalized US veterans, resulting in severe disease. Clinicians should remain vigilant for bacterial and viral causes of AGE year-round.

Indexed as

Caliciviridae InfectionsClostridioides difficileGastroenteritisRotavirusVeteransAdultAgedFecesHospitals, VeteransHumansIncidenceInfantOutpatientsProspective StudiesUnited States

Identifiers

PMID32584956
PMCPMC9195496
OpenAlexW3037489448

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.